Raltegravir Plus Abacavir/lamivudine in Virologically Suppressed HIV-1-infected Patients: 48-Week Results of the KIRAL Study.
PLoS ONE（2018）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined